- Home
- ACRE vs ENGN Comparison
ACRE vs ENGN Comparison
Compare ACRE & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- ENGN
- Stock Information
- Founded
- ACRE 2011
- ENGN 1999
- Country
- ACRE United States
- ENGN Canada
- Employees
- ACRE N/A
- ENGN N/A
- Industry
- ACRE Real Estate Investment Trusts
- ENGN
- Sector
- ACRE Real Estate
- ENGN
- Exchange
- ACRE Nasdaq
- ENGN Nasdaq
- Market Cap
- ACRE 358.1M
- ENGN 293.1M
- IPO Year
- ACRE 2012
- ENGN N/A
- Fundamental
- Price
- ACRE $6.39
- ENGN $5.83
- Analyst Decision
- ACRE Hold
- ENGN Strong Buy
- Analyst Count
- ACRE 7
- ENGN 8
- Target Price
- ACRE $7.10
- ENGN $30.38
- AVG Volume (30 Days)
- ACRE 694.6K
- ENGN 200.8K
- Earning Date
- ACRE 02-20-2025
- ENGN 12-19-2024
- Dividend Yield
- ACRE 15.65%
- ENGN N/A
- EPS Growth
- ACRE N/A
- ENGN N/A
- EPS
- ACRE N/A
- ENGN N/A
- Revenue
- ACRE $39,423,000.00
- ENGN N/A
- Revenue This Year
- ACRE N/A
- ENGN N/A
- Revenue Next Year
- ACRE N/A
- ENGN N/A
- P/E Ratio
- ACRE N/A
- ENGN N/A
- Revenue Growth
- ACRE N/A
- ENGN N/A
- 52 Week Low
- ACRE $6.02
- ENGN $4.42
- 52 Week High
- ACRE $11.24
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ACRE 36.68
- ENGN 26.75
- Support Level
- ACRE $7.04
- ENGN $5.68
- Resistance Level
- ACRE $7.27
- ENGN $6.55
- Average True Range (ATR)
- ACRE 0.21
- ENGN 0.69
- MACD
- ACRE -0.11
- ENGN -0.24
- Stochastic Oscillator
- ACRE 29.60
- ENGN 6.99
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.